Back to top
more

Sarepta Therapeutics (SRPT)

(Delayed Data from NSDQ)

$133.34 USD

133.34
1,015,004

+0.26 (0.20%)

Updated Aug 15, 2024 04:00 PM ET

After-Market: $133.39 +0.05 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (80 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Sarepta (SRPT) Q2 Loss Narrows, Exondys 51 Drives Sales

Sarepta's (SRPT) loss per share is narrower than the Zacks Consensus Estimate while sales also beat the same. Exondys 51 continues its strong performance.

    Implied Volatility Surging for Sarepta Therapeutics (SRPT) Stock Options

    Investors in Sarepta Therapeutics (SRPT) need to pay close attention to the stock based on moves in the options market lately.

      Sarepta Therapeutics (SRPT) Reports Q2 Loss, Tops Revenue Estimates

      Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 8.51% and 3.66%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

        Jazz Pharma (JAZZ) Q2 Earnings Coming Up: What's in Store?

        Jazz's (JAZZ) Xyrem will likely continue to do well in the second quarter. Supply constraints will continue to hurt sales of Erwinaze.

          Is a Beat in Store for BioDelivery (BDSI) in Q2 Earnings?

          Investor focus will be on the performance of BioDelivery Sciences' (BDSI) two marketed drugs, Belbuca (chronic pain) and Bunavail (opioid-dependence).

            Should First Trust Mid Cap Growth AlphaDEX Fund (FNY) Be on Your Investing Radar?

            Style Box ETF report for FNY

              Sarepta's DMD Portfolio Solid, Sole Drug Dependence Concerns

              Sarepta Therapeutics' (SRPT) DMD drug sales are rising and pipeline candidates are progressing well. However, dependence on a single product for near-term growth is a concern.

                Indrajit Bandyopadhyay headshot

                DMD Research Veers Toward Gene Therapy: 3 Stocks in Focus

                Investor focus is on the DMD segment this week with Sarepta presenting encouraging gene therapy study data and the FDA lifting its clinical hold on Solid Biosciences' gene therapy study.

                  Sweta Killa headshot

                  Sarepta Pharma Pushes Two Biotech ETFs to New Highs

                  The encouraging early trial results for a gene therapy for Duchenne muscular dystrophy pushed Sarepta Therapeutics and few biotech ETFs to new highs.

                    Company News For Jun 20, 2018

                    Companies in the news are: T,FMI,COTV,SRPT

                      Biotech Stock Roundup: SRPT & SLDB Soar on Positive Data, ANIK & ZIOP Crash

                      The biotech sector showed volatility with a few companies gaining on positive data readouts while a few plunging on dismal results.

                        Sarepta's Stock Soars on Encouraging Gene Therapy Results

                        Sarepta (SRPT) shares skyrocket on better-than-expected results from an early-stage study, evaluating its gene therapy as a treatment for DMD patients.

                          Solid (SLDB) Surges as FDA Lifts Clinical Hold on DMD Drug

                          Solid Biosciences' (SLDB) shares gained significantly after the FDA lifted the clinical hold on its phase I/II trial for its lead candidate, SGT-001 for DMD.

                            Options Traders Expect Huge Moves in Sarepta (SRPT) Stock

                            Sarepta (SRPT) needs investors to pay close attention to the stock based on moves in the options market lately.

                              Sarepta Inks Manufacturing Deal for Gene Therapy Program

                              Sarepta (SRPT) strikes manufacturing partnership with Brammer Bio to support its gene therapy development.

                                Here's Why Sarepta is Up More Than 60% So Far This Year

                                Sarepta's (SRPT) key product, Exondys 51, continue to perform well and lead pipeline candidate, golodirsen, progresses well in 2018.

                                  Sarepta (SRPT) Q1 Loss Narrows, Exondys 51 Sales Impress

                                  Sarepta (SRPT) reports narrower-than-expected loss for the first quarter of 2018. However, sales miss estimates.

                                    Pfizer Starts Phase Ib for Duchenne Muscular Dystrophy Drug

                                    Pfizer (PFE) commences dosing in a phase Ib study, evaluating its gene therapy candidate, PF-06939926, for treating five to 12-yearold boys with duchenne muscular dystrophy.

                                      Why Is Sarepta Therapeutics (SRPT) Up 19.3% Since Its Last Earnings Report?

                                      Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                        Solid Biosciences (SLDB) Hit by Clinical Hold on Lead Drug

                                        Shares of Solid Biosciences (SLDB) were hit after the FDA put a clinical hold on a phase III study of lead DMD candidate, SGT-001.

                                          Sarepta to Seek Rapid Approval for Second DMD Drug, Stock Up

                                          Sarepta (SRPT) will file a rolling NDA for its second DMD drug, golodirsen. The submission is expected to be completed in late 2018.

                                            Zacks Investment Ideas feature highlights: Sarepta Therapeutics, bluebird bio, Editas Medicine, Align Technology and Intellia Therapeutics

                                            Zacks Investment Ideas feature highlights: Sarepta Therapeutics, bluebird bio, Editas Medicine, Align Technology and Intellia Therapeutics

                                              Kevin Cook headshot

                                              Why Sarepta (SRPT) Jumped and We Sold

                                              Gains have rewarded the patient, but the long-term is balanced with obstacles still ahead in the FDA gauntlet

                                                Zacks Investment Ideas feature highlights: Sangamo, bluebird, Editas, Sarepta and Juno

                                                Zacks Investment Ideas feature highlights: Sangamo, bluebird, Editas, Sarepta and Juno

                                                  Kevin Cook headshot

                                                  Healthcare Heroes That Aren't Done Yet

                                                  Key growth stocks across medical industries tell you the megatrends are in full force for years to come